Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 6,732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Management Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test
Other · Behavioral · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 6:56 AM EDT
Enrolling by invitation No phase listed Observational

Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home

NCT06488846
View directory record Official record
Conditions
HIV Infections
Interventions
INVITE-Home, Clinic-Administered LAI-ART, Oral ART
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Early Phase 1 Interventional

Evaluation of NV701 (Pilocarpine 1.25%) Compared With Vuity (Pilocarpine 1.25%) on Pupil Size in Subjects With Presbyopia

NCT06783686
View directory record Official record
Conditions
Pupil Constriction
Interventions
NV701, Pilocarpine 1.25% Eye drop
Drug
Lead sponsor
Novus Vision LLC
Industry
Eligibility
40 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Chandler, Arizona • Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

NCT01749969
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
isatuximab SAR650984, lenalidomide, dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

NCT04701983
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab SAR440340, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
75
States / cities
Birmingham, Alabama • Jasper, Alabama • Chandler, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Not applicable Interventional

Contingency Management for Drug Use: Does Age Matter?

NCT05521854
View directory record Official record
Conditions
Opioid Use Disorder, Methamphetamine Abuse, Cocaine Use Disorder
Interventions
DynamiCare app (app-based contingency management), Sham control
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Not applicable Interventional

Pilot Study of Adjunctive Yoga for Bipolar Depression

NCT02402010
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Adjunctive Yoga, Enhanced Treatment as Usual
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients

NCT04376762
View directory record Official record
Conditions
Pediatric HD, Bleeding
Interventions
Fibrinogen, Cryoprecipitate
Drug
Lead sponsor
University of Virginia
Other
Eligibility
Up to 24 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid vs Saline (DysDexVSSal)

NCT03711474
View directory record Official record
Conditions
Dysphagia
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

Patient Controlled Administration of Liquid Acetaminophen

NCT06498713
View directory record Official record
Conditions
Pain, Pain, Postoperative
Interventions
Acetaminophen 650 mg Oral Tablet, Acetaminophen 650mg Liquid, CADD pump
Drug · Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Not applicable Interventional Results available

Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB

NCT04129346
View directory record Official record
Conditions
Metastatic Breast Cancer, Obesity
Interventions
Fit2ThriveMB App, Fitbit, Physical Activity Coaching Calls, Healthy Living Coaching Calls, Cancer.net app
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 21, 2026, 6:56 AM EDT
Recruiting Not applicable Interventional

Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment

NCT06454903
View directory record Official record
Conditions
Opioid-Related Disorders, Psychosocial Functioning, Quality of Life
Interventions
ACT to RECOVER, Smartphone-based Symptom-Monitoring
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 6:56 AM EDT
Recruiting Not applicable Interventional

Opioid Tapering After Hospital Discharge: Testing an Intervention to Improve Post-operative Opioid Prescribing

NCT07510373
View directory record Official record
Conditions
Opioid Tapering
Interventions
Treatment as Usual (TAU), Telephonic Support (TS) Providers, DOTS Intervention
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 6:56 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Noise-Induced Hearing Loss-Acute Exposure Treatment

NCT04768569
View directory record Official record
Conditions
Hearing Loss, Noise-Induced
Interventions
Zonisamide 100Mg Cap, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 21, 2026, 6:56 AM EDT
Terminated Phase 3 Interventional

Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma

NCT00907413
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
ERCP and Photodynamic Therapy, ERCP only
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlotteville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

NCT04523220
View directory record Official record
Conditions
End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
Interventions
BAY1213790 (Osocimab), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Azusa, California • Brawley, California • Encino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)

NCT00286182
View directory record Official record
Conditions
Anemia
Interventions
Erythropoietin alpha, Placebo
Drug
Lead sponsor
Mathew S. Maurer
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105

NCT03043482
View directory record Official record
Conditions
Chronic-kidney Disease Stage 5D on Stable Hemodialysis
Interventions
Single VS-105/placebo to healthy, Multiple VS-105/placebo to healthy, Multiple VS-105/placebo to HD subjects
Drug
Lead sponsor
Vidasym, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 21, 2026, 6:56 AM EDT
Suspended Phase 2 Interventional

A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

NCT00002424
View directory record Official record
Conditions
HIV Infections
Interventions
L-756423, Indinavir sulfate, Lamivudine, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

NCT06546423
View directory record Official record
Conditions
Human Metapneumovirus, Human Parainfluenza Virus Type 3
Interventions
B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
24 Months to 59 Months
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Baltimore, Maryland • Columbia, Maryland • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 6:56 AM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 6:56 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

NCT03684642
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide, Dulaglutide, Background therapy Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

NCT00703313
View directory record Official record
Conditions
Healthy
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 21, 2026, 6:56 AM EDT
Completed Not applicable Interventional

REACH-Es: Adapting a Digital Health Tool to Improve Diabetes Medication Adherence Among Latino Adults

NCT06000813
View directory record Official record
Conditions
Type 2 Diabetes (Adult Onset), Medication Adherence
Interventions
REACH-Es, ETAU
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 6:56 AM EDT